Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending April 17, 2018. The document serves as a transaction notification regarding dealings in the company's ordinary shares by Persons Discharging Managerial Responsibilities (PDMRs).
Key Financial Metrics
The filing does not provide financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. It is strictly a regulatory disclosure of specific share transactions.
Material Changes and Transaction Details
The filing discloses two separate transactions involving the acquisition of ordinary shares by PDMRs. Both transactions occurred on April 13, 2018, on the London Stock Exchange (XLON) at a price of £14.25 per share. The acquisitions resulted from the reinvestment of dividends paid on April 12, 2018, on shares held within Individual Savings Accounts (ISAs).
- Mr. D S Redfern (Chief Strategy Officer): Acquired 30 ordinary shares.
- Mrs. V A Whyte (Company Secretary): Acquired 26 ordinary shares.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, risk factors, contingencies, or unusual items. It is a routine compliance notification under Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934.
Key Facts for Investor Verification
- Transactions were automatic dividend reinvestments, not discretionary open-market purchases.
- Both transactions occurred at the same price point (£14.25) on the same date (April 13, 2018).
- The total volume of shares acquired by these two executives in this specific notification was 56 shares.
- The filing confirms the Company Secretary, Victoria Whyte, as the authorized signatory.